Literature DB >> 22795209

Overview of treatment options in multiple sclerosis.

Emmanuelle Waubant1.   

Abstract

Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system that results in inflammation, demyelination, and axonal and neuronal loss. The typical course of MS is one of symptom exacerbations followed by periods of remission; however, patients will eventually accrue disability from the exacerbations. Several drugs, including interferon beta, glatiramer acetate, natalizumab, and fingolimod, are effective in lowering relapse rates and slowing the progression of MS. For patients with suboptimal response to medication, switching to another first- or second-line medication can be an effective strategy. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795209     DOI: 10.4088/JCP.11006nr2c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

Review 1.  Laquinimod therapy in multiple sclerosis: a comprehensive review.

Authors:  Channa Kolb-Sobieraj; Sahil Gupta; Bianca Weinstock-Guttman
Journal:  Neurol Ther       Date:  2014-05-06

2.  Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.

Authors:  Cris S Constantinescu; Aliya Asher; Waldemar Fryze; Wojciech Kozubski; Frank Wagner; Jehan Aram; Radu Tanasescu; Roman P Korolkiewicz; Maren Dirnberger-Hertweck; Stefan Steidl; Susan E Libretto; Till Sprenger; Ernst W Radue
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-05-21

3.  pVAXhsp65 Vaccination Primes for High IL-10 Production and Decreases Experimental Encephalomyelitis Severity.

Authors:  Sofia Fernanda Gonçalves Zorzella-Pezavento; Fernanda Chiuso-Minicucci; Thais Graziela Donegá França; Larissa Lumi Watanabe Ishikawa; Larissa Camargo da Rosa; Priscila Maria Colavite; Bianca Balbino; Camila Marques; Maura Rosane Valerio Ikoma; Ana Paula Masson; Célio Lopes Silva; Alexandrina Sartori
Journal:  J Immunol Res       Date:  2017-02-21       Impact factor: 4.818

4.  Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis.

Authors:  Fay Probert; Tianrong Yeo; Yifan Zhou; Megan Sealey; Siddharth Arora; Jacqueline Palace; Timothy D W Claridge; Rainer Hillenbrand; Johanna Oechtering; David Leppert; Jens Kuhle; Daniel C Anthony
Journal:  Brain Commun       Date:  2021-04-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.